Now, eye specialists say they may also affect sight.
As medications like Ozempic spread from diabetes clinics to celebrity wellness routines, fresh data is raising questions about a rare but serious eye problem that can abruptly rob people of their vision.
From diabetes breakthrough to weight-loss craze
Ozempic, Wegovy and Rybelsus all contain semaglutide, a drug that mimics a natural gut hormone known as GLP-1. This hormone helps the pancreas release insulin, lowers blood sugar and slows digestion, which leaves people feeling full sooner.
For people with type 2 diabetes, semaglutide has been a genuine breakthrough. Many lose substantial weight, see improved blood pressure and cholesterol levels, and reduce their risk of heart attacks and strokes.
That medical success quickly spilled outside specialist clinics. Posts about rapid weight loss on TikTok, Instagram and Reddit pushed semaglutide into the mainstream. Demand soared, shortages hit pharmacies and off-label prescriptions for people without diabetes became common.
Behind the hype, researchers are now studying whether GLP-1 drugs might, in very rare cases, compromise the blood flow that keeps the optic nerve alive.
The potential problem is not a mild side effect like nausea or constipation. It concerns a rare condition sometimes nicknamed a “stroke of the eye”.
A rare but alarming eye condition
The condition under scrutiny is called non-arteritic anterior ischaemic optic neuropathy, or NAION. It appears when blood flow to the optic nerve drops suddenly. Without oxygen, part of the nerve dies.
Symptoms usually strike out of the blue. People may wake up with dim or blurry vision in one eye, a dark patch in their field of view, or notice that colours look washed out. There is usually no pain.
Once vision is lost, doctors have few tools to restore it. Some patients keep partial sight; others lose most central vision in the affected eye for good.
➡️ This gentle method degreases stainless steel range hoods without scratches or streaks
➡️ China gives Airbus an early Christmas gift as symbolic production milestone is reached at Tianjin plant
➡️ Persimmons are praised for their health benefits, but eating them at the wrong stage can cause unexpected digestive issues
➡️ Mocha mousse hair dye: subtle highlights for natural brunettes
➡️ Pellets: the little-known trick to save big on your heating before autumn
➡️ The date is set: the longest solar eclipse of the century will turn day into night
➡️ If you feel disconnected from your emotions, psychology explains this coping response
➡️ The cleaning mistake that makes rooms feel unfinished
NAION is rare – only a few cases per 100,000 people each year – but its consequences can be lifelong and disabling.
Regulators in Europe have already taken note. In 2025, the European Medicines Agency added NAION to the list of “very rare” potential side effects for semaglutide, recommending that patients stop treatment and seek urgent care if they notice sudden vision changes.
What the new studies actually found
Higher rates of vision loss in semaglutide users
The first major warning signal came from a study at Massachusetts Eye and Ear Hospital, which followed patients between 2017 and 2023. Researchers compared people with diabetes or obesity who used semaglutide with similar patients who did not.
Among more than 16,000 patients, those on semaglutide had a markedly higher rate of NAION:
- People with diabetes on semaglutide: around four times the risk of NAION
- People with obesity on semaglutide: more than seven times the risk
The findings were published in JAMA Ophthalmology in 2024 and attracted global attention. The study does not prove semaglutide directly causes NAION. Observational research can show associations but cannot rule out other factors, such as blood pressure swings, sleep apnoea or existing eye disease.
The size of the study and the size of the risk increase mean the signal cannot be brushed aside as pure coincidence.
A second study points in the same direction
A separate team from the Karolinska Institutet in Sweden and the University of Melbourne examined national health data. They found that NAION remained very uncommon overall – affecting about 0.04% of people on GLP-1 drugs – but was slightly more frequent than in matched individuals who did not take these medications.
The interpretation is tricky. Diabetes itself is a known risk factor for NAION. A meta-analysis published in PLOS ONE back in 2013 suggested that diabetes raised the risk of this optic nerve condition by around 64%. Many semaglutide users also have high blood pressure, high cholesterol or sleep apnoea, which also strain the eye’s microcirculation.
Researchers are now trying to tease apart whether semaglutide adds an extra layer of risk on top of those conditions, or whether the apparent signal stems from the underlying diseases that the drug is designed to treat.
How might a weight-loss drug affect the eyes?
The exact mechanism linking GLP-1 drugs and NAION, if one exists, remains uncertain. Specialists have floated a few plausible pathways:
- Rapid metabolic shifts: Fast improvements in blood sugar and blood pressure may alter blood flow in tiny vessels that feed the optic nerve.
- Night-time blood pressure drops: Some people with sleep apnoea or on blood pressure medication already experience low blood pressure at night, a known risk factor for NAION. Adding semaglutide could accentuate this in susceptible patients.
- Anatomical vulnerability: People with a “crowded” optic disc – a tight exit point where the nerve enters the eye – seem more prone to NAION. Any slight reduction in blood supply may hit them harder.
Not everyone carries the same level of risk: the structure of the optic nerve, sleep disorders and cardiovascular health all play a part.
Balancing weight-loss benefits against eye risks
For doctors, the dilemma is real but nuanced. Semaglutide does not just shrink waistlines. It lowers the chance of heart attacks, strokes and premature death in many high-risk patients. Those are common, life-threatening problems; NAION is rare and affects a small minority.
Eye specialists and endocrinologists generally agree that for most patients with obesity or type 2 diabetes, the benefits of semaglutide still outweigh the potential harms. That balance may shift for people with specific vulnerabilities.
Who may need closer monitoring?
Clinicians are paying particular attention to patients who have:
- a history of NAION in one eye
- significant sleep apnoea
- poorly controlled high blood pressure
- known optic nerve anomalies, such as a crowded optic disc
- existing serious eye disease linked to diabetes
For these individuals, starting a GLP-1 drug might prompt an eye exam first, then regular check-ups. A simple note in the medical record stating that the person takes semaglutide can nudge opticians and ophthalmologists to look more closely at the optic nerve during routine visits.
Any sudden visual change while using semaglutide should be treated as an emergency, not something to “wait and see”.
Practical advice for current and future users
Symptoms that need urgent attention
People on Ozempic, Wegovy, Rybelsus or similar GLP-1 drugs should seek urgent care if they notice:
- sudden blurry or dim vision in one eye
- a dark or shadowed area in part of their visual field
- colours looking unusually faded
- vision changes on waking that do not clear within minutes
Doctors will not diagnose NAION over the phone. Patients usually need an urgent in-person eye exam and sometimes imaging of the optic nerve. In many countries, emergency departments can refer quickly to on-call ophthalmology teams.
Questions to ask your doctor
Before starting or continuing a GLP-1 drug, some useful questions include:
- Do I have other NAION risk factors, such as sleep apnoea or high blood pressure?
- Should I see an eye specialist before increasing my dose?
- What early warning signs should I watch for?
- How quickly can I stop the medication if eye symptoms appear?
| Aspect | Potential benefit | Potential risk |
|---|---|---|
| Weight | Significant loss (often 10–15% of body weight) | Rapid change may stress existing eye or cardiovascular issues |
| Heart and vessels | Lower risk of heart attack and stroke in high-risk patients | Possible blood-flow shifts affecting optic nerve in rare cases |
| Vision | No direct benefit; possible indirect benefit through better diabetes control | Very rare risk of NAION and sudden vision loss |
Key terms patients keep hearing
The debate around Ozempic and sight often uses jargon that can sound abstract. Two concepts crop up frequently:
- GLP-1 receptor agonist: A drug that behaves like the natural GLP-1 hormone, telling the body to release insulin, curb appetite and slow digestion.
- Microcirculation: The network of tiny blood vessels that supply organs with oxygen. In the eye, this microcirculation keeps the retina and optic nerve functioning.
When doctors talk about these drugs “affecting the microcirculation of the eye”, they are not suggesting that everyone will notice something. They are asking whether, in a small number of sensitive people, these shifts might push an already fragile optic nerve over the edge.
What the next few years may reveal
Several large-scale projects are underway to clarify the picture. One long-term study is following around 1,500 patients for five years, tracking changes to the retina and optic nerve with high-resolution imaging while they use semaglutide.
Those results will help answer questions patients are already asking in clinics: is this risk confined to certain doses, specific GLP-1 drugs or particular patient profiles? Or does any strong improvement in metabolic health carry a small, temporary penalty for some people’s eyes?
Until better data arrive, the message from specialists is straightforward: take vision changes seriously, keep regular eye checks if you are on these medications, and have an honest conversation with your doctor about where your personal benefit–risk balance lies.